Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

NCT01422772 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Ischemic Heart Disease

Interventions

BIOLOGICAL: VM202-0.5 mg
BIOLOGICAL: VM202-1.0 mg
BIOLOGICAL: VM202-2.0 mg

Sponsor

Helixmith Co., Ltd.